Table 1 .
Characteristics and clinical course of presented patients.
|
Case 1 |
Case 2 |
Case 3 |
|
|---|---|---|---|
|
Age (years)/Sex |
7/M |
18/M |
6/F |
|
Disease |
Neuroblastoma |
Aplastic anemia |
Aplastic anemia |
|
Stem cell source |
Unrelated cord blood |
Unrelated bone marrow |
Unrelated bone marrow |
|
HLA match (allele) |
3/6 |
4/6 |
4/6 |
|
Conditioning regimen |
FLU + MEL + TBI 2 Gy |
FLU + MEL + rabbit ATG (total 5.0 mg/kg) + TBI 2Gy |
FLU + MEL + rabbit ATG (total 5.0mg/kg) + TBI 3Gy |
|
Total infused nucleated cells (cells/kg body weight) |
12.7 × 107 |
2.0 × 108 |
1.6 × 108 |
|
GVHD prophylaxis |
TAC + MTX |
MMF + MTX + mPSL |
TAC + MTX |
|
Onset of GI tract GVHD |
Day 20 |
Day 32 |
Day 101 |
|
Severity of GI tract GVHD |
Stage 4 |
Stage 3 |
Stage 2 |
|
Severity of co-existing GVHD |
Skin: stage 1 |
None |
None |
|
Treatment for GVHD before the start of oral BDP |
TAC + MTX + mPSL + MMF |
MMF + mPSL |
TAC + PSL |
|
Start date of oral BDP |
Day 94 |
Day 44 |
Day 148 |
|
Therapeutic response |
Effective |
Effective |
Effective |
|
Period from the start of oral BDP to improvement of abdominal pain (days) |
3 |
7 |
5 |
|
Period from the start of oral BDP to improvement of diarrhea (weeks) |
3 |
2 |
2 |
|
Duraion of oral BDP administration (days) |
229 |
41 |
305 |
|
CMV disease during treatment with oral BDP |
CMV antigenemia |
No |
No |
|
Other infectious complications during treatment with oral BDP |
No |
Sepsis (Acinetobacter Iwoffii) |
No |
|
Potential adverse event associated with oral BDP (other than infectious complications) |
No |
No |
Growth restriction |
|
Recurrence of GI tract GVHD after the cessation of oral BDP |
No |
No |
No |
|
Survival |
Alive |
Alive |
Alive |